Intellectual Property

EndGenitor has licensed (from Indiana University Research & Technology Corporation) technology relating to proprietary, novel, and highly proliferative stem cell populations that mature into the lining of new blood vessels. This technology is patent pending.

EndGenitor scientists are also engaged in exciting research which could lead to novel methods for stimulating and promoting blood vessel formation and growth.

Related publications by our Scientific Consultants

• Ingram DA, et al, "Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood", Blood, 2004 Nov 1;104(9):2752-60.
• Bessler M, "Endothelial progenitor cells: reporting for duty", Blood, 2004 Nov 1;104(9):2616-7.
• Ingram DA, et al, "Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells", Blood, 2005 Apr 1;105(7)2783-6.
• Ingram DA, Caplice NM, Yoder MC, "Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells", Blood, 2005 Sep 1;106(5)1525-31.
• Yoder MC, "General concepts about stem cells as potential therapeutic agents", NeoReviews, 2003, Jul;4(7):e175-80.

EndGenitor's ECFCs® differentiating to form tube-like capillaries when stimulated in vitro.